Enovis Corporation reported 9% sales growth in the third quarter, with Reconstructive sales up 12% year-over-year. They divested their Diabetic Footcare business unit for up to $60 million in October. The company raised its full-year adjusted EBITDA and EPS guidance. Enovis delivered a net loss of $571 million, with adjusted EBITDA of $95 million. The CEO highlighted double-digit growth in extremities and consistent performance across Prevention & Recovery. Enovis updated its 2025 revenue to be in the range of $2.24-2.27 billion, with adjusted EBITDA forecasted at $395-405 million and adjusted EPS guidance at $3.10-3.25.

The company’s third-quarter net sales grew 9% on a reported basis and 7% organically, with net loss of $571 million. Adjusted net earnings per diluted share were $0.75. Enovis raised its full-year 2025 adjusted EBITDA and adjusted EPS guidance. They also divested their Diabetic Footcare business unit in October for up to $60 million. The company reported continued execution in P&R and Recon, with stable end markets and new product introductions showing momentum. Enovis is focusing on commercial execution, innovation, operational excellence, and financial discipline for future growth. Investors can access the webcast of the results discussion on the Enovis website.

Read more at GlobeNewswire: Enovis Announces Third Quarter 2025 Results